420 completed, 46 terminated, 17 unknown, 15 withdrawn. 502 Phase 1, 37 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 502 | Completed 420, Terminated 46, Unknown 17, Withdrawn 15, Suspended 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 37 | Completed 28, Terminated 4, Unknown 3, Recruiting 1, Withdrawn 1 |
Follow Unspecified Adult Solid Tumor, Protocol Specific: new trials by email Literature Review of Unspecified Adult Solid Tumor, Protocol Specific trials Research Report on Unspecified Adult Solid Tumor, Protocol Specific
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI CP-506, Carboplatin, Immune checkpoint inhibitor - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Recruiting | Maastricht University Medical Center | 126 | 2023-05-30 | 2025-10-07 |
| A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors SHR-1916 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 11 | 2021-04-08 | 2024-02-09 |
| TR1801-ADC in Patients With Tumors That Express c-Met TR1801-ADC - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Suspended | Open Innovation Partners, Inc. | 15 | 2019-08-14 | 2023-09-22 |
| RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists RNR inhibitor COH29, laboratory biomarker analysis, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Active not recruiting | City of Hope Medical Center | 12 | 2017-01-09 | 2026-10-20 |
| A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors NKTR-214 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Completed | Nektar Therapeutics | 28 | 2015-12-01 | 2021-07-29 |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer dovitinib lactate, gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation - Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2015-03-01 | 2015-01-09 | |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors VEGFR/PDGFR dual kinase inhibitor X-82, docetaxel, fluorine F 18 fluorothymidine - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Wisconsin, Madison | 14 | 2014-09-01 | 2019-11-18 |
| Icotinib Hydrochloride in Treating Patients With Advanced Cancers icotinib hydrochloride, laboratory biomarker analysis, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2014-08-01 | 2014-11-05 | |
| Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 4 | 2014-07-17 | 2019-02-28 |
| Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer BKM120, cisplatin, etoposide - Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of California, Davis | 3 | 2014-07-01 | 2018-01-09 |
| Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors nanosomal docetaxel lipid suspension, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Southern California | 13 | 2013-11-08 | 2017-04-11 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection vorinostat, diagnostic laboratory biomarker analysis, pharmacological study - HIV Infection, Recurrent Anal Cancer | Phase 1 | Terminated | AIDS Malignancy Consortium | 17 | 2013-11-01 | 2020-07-29 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer alisertib, gemcitabine - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1 | Completed | Edward Kim | 26 | 2013-08-09 | 2022-08-02 |
| Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer auranofin, sirolimus, laboratory biomarker analysis - Recurrent Non-small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Withdrawn | Mayo Clinic | 2013-08-01 | 2016-08-26 | |
| Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer irinotecan hydrochloride, alisertib - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 1 | Completed | University of California, Davis | 17 | 2013-08-01 | 2019-01-04 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2013-05-01 | 2014-09-25 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors KX2-391 and Paclitaxel - Unspecified Adult Solid Tumor, Protocol Specific, Gastric Cancer | Phase 1 / Phase 2 | Unknown | Hanmi Pharmaceutical Company Limited | 60 | 2012-12-01 | 2015-05-18 |
Showing 20 of 502. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (81) · Lymphoma, Follicular (81) · Lymphoma, B-Cell, Marginal Zone (80) · Lymphoma, Mantle-Cell (80) · Lymphoma, Non-Hodgkin (80) · Burkitt Lymphoma (79) · Lymphoma, Large B-Cell, Diffuse (79) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (79) · Lymphoma, Large-Cell, Immunoblastic (78) · Hodgkin Disease (66) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (63) · Lymphoma (61) · Lymphoma, Large-Cell, Anaplastic (60) · Immunoblastic Lymphadenopathy (59) · Lymphoma, T-Cell, Cutaneous (50)
Neoplasms (177) · Neoplasms by Site (141) · Neoplasms by Histologic Type (130) · Hemic and Lymphatic Diseases (93) · Pathological Conditions, Signs and Symptoms (92) · Hematologic Diseases (90) · Immune System Diseases (90) · Immunoproliferative Disorders (89) · Pathologic Processes (89) · Lymphatic Diseases (87) · Disease Attributes (84) · Lymphoproliferative Disorders (84) · Chronic Disease (83) · Leukemia, Lymphoid (83) · Virus Diseases (82)
Gemcitabine (38) · Irinotecan (38) · Paclitaxel (37) · Cisplatin (33) · Docetaxel (29) · Carboplatin (26) · Bortezomib (22) · Capecitabine (21) · Fluorouracil (20) · Oxaliplatin (20) · Leucovorin (17) · alvocidib (16) · Taxes (14) · Topotecan (13) · tanespimycin (13)
National Cancer Institute (NCI) (140) · Memorial Sloan Kettering Cancer Center (33) · City of Hope Medical Center (20) · Roswell Park Cancer Institute (18) · European Organisation for Research and Treatment of Cancer - EORTC (14) · Case Comprehensive Cancer Center (13) · Mayo Clinic (13) · University of California, Davis (13) · National Institutes of Health Clinical Center (CC) (12) · NCIC Clinical Trials Group (11) · Jonsson Comprehensive Cancer Center (10) · The University of Texas Health Science Center at San Antonio (8) · Vion Pharmaceuticals (8) · Barbara Ann Karmanos Cancer Institute (7) · Fox Chase Cancer Center (6)
United States (428) · Canada (23) · United Kingdom (19) · Germany (13) · France (12) · Netherlands (12) · Belgium (10) · Norway (9) · Austria (8) · Denmark (8) · Switzerland (8) · New Zealand (4) · South Korea (4) · Spain (4) · Australia (2)
Mario Sznol, MD (9) · Gary K. Schwartz, MD (8) · David R. Spriggs, MD (7) · George Wilding (6) · Alex Adjei (5) · Charles Erlichman (5) · Eric K. Rowinsky, MD (5) · Franco M. Muggia, MD (5) · Angela Davies, MD (4) · David R. Gandara, MD (4) · Howard S. Hochster, MD (4) · Patricia M. LoRusso, DO (4) · Ross C. Donehower, MD (4) · Scot C. Remick, MD (4) · Shivaani Kummar, MD (4)
PMID 20028764, PMID 10442378, PMID 10815886, PMID 11211153, PMID 11331328, PMID 11410496, PMID 12114401, PMID 12231519, PMID 12473581, PMID 12525514, PMID 12702532, PMID 12807934, PMID 12963697, PMID 14555506, PMID 14630685, PMID 14767498, PMID 15033677, PMID 15122073, PMID 15711184, PMID 15763645, PMID 15958629, PMID 15961763, PMID 16135477, PMID 16391300, PMID 16428495, PMID 16683073, PMID 17084620, PMID 17145828, PMID 17261851, PMID 17404091, PMID 17414457, PMID 17429623, PMID 17699864, PMID 17989978, PMID 18053191, PMID 18090584, PMID 18245546, PMID 18322686, PMID 18327587, PMID 18398152, PMID 18414865, PMID 18451235, PMID 18519811, PMID 18602257, PMID 18626572, PMID 18757332, PMID 19011760, PMID 19219674, PMID 19221754, PMID 19238148
U01CA062505 (22), U01CA062491 (17), P30CA033572 (15), U01CA062502 (15), P30CA043703 (14), P30CA014520 (13), U01CA062487 (12), U01CA069912 (12), P30CA015083 (11), P30CA093373 (9), U01CA099168 (9), P30CA022453 (8), U01CA069856 (8), P30CA054174 (7), U01CA062490 (7)